Bioxytran, Inc. (OTCMKTS:BIXT) Short Interest Up 4,632.7% in May

Bioxytran, Inc. (OTCMKTS:BIXT) was the target of a significant growth in short interest in the month of May. As of May 15th, there was short interest totaling 14,198 shares, a growth of 4,632.7% from the April 30th total of 300 shares. Approximately 0.0% of the company’s shares are sold short. Based on an average daily volume of 81,682 shares, the short-interest ratio is currently 0.2 days.

Bioxytran Stock Performance

Shares of BIXT stock remained flat at $0.03 on Wednesday. The stock had a trading volume of 35,617 shares, compared to its average volume of 279,913. Bioxytran has a 12 month low of $0.03 and a 12 month high of $0.16. The stock has a market cap of $3.43 million, a price-to-earnings ratio of -1.50 and a beta of 1.95. The company’s fifty day moving average price is $0.04 and its 200-day moving average price is $0.05.

Bioxytran (OTCMKTS:BIXT) last announced its earnings results on Friday, May 15th. The company reported ($0.02) EPS for the quarter.

Bioxytran Company Profile

Bioxytran, Inc is a clinical-stage biotechnology company focused on the development of synthetic oxygen carriers and novel oxygen therapeutics for acute care and chronic disease applications. The company’s proprietary platform is designed to safely deliver therapeutic levels of oxygen to hypoxic tissues, addressing conditions such as ischemia-reperfusion injury, organ transplantation, and traumatic injury. Its lead product candidates target unmet medical needs in cardiovascular and neurological disorders, wound healing, and critical care settings.

Bioxytran’s research pipeline comprises multiple preclinical-stage assets that leverage stabilized perfluorocarbon emulsions to achieve controlled oxygen release.